Eli Lilly and (LLY)
820.02
-1.65 (-0.20%)
At close: Mar 28, 2025, 3:59 PM
816.77
-0.40%
After-hours: Mar 28, 2025, 06:59 PM EDT
Eli Lilly and Revenue Breakdown
| Quarter | Sep 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Jun 30, 2011 | Mar 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunology Revenue | 1.19B | 834M | 986.9M | 928.5M | 777.8M | 866.4M | 796.5M | 748.1M | 1B | 785.4M | 613.9M | 627.1M | 548.3M | 585.8M | 454.6M | 456.1M | 334.7M | 894.5M | 966.9M | 861.3M | 922.6M | 759M | 887.9M | 869.9M | 893.7M | 964.4M | 1.48B | 1.88B | 2B | 1.85B | 2.03B | 1.82B | 1.82B | 1.9B | 2.65B | 53.6M |
| Immunology Revenue Growth | +42.17% | -15.49% | +6.29% | +19.38% | -10.23% | +8.78% | +6.47% | -25.55% | +27.95% | +27.94% | -2.10% | +14.37% | -6.40% | +28.86% | -0.33% | +36.27% | -62.58% | -7.49% | +12.26% | -6.64% | +21.55% | -14.52% | +2.07% | -2.66% | -7.33% | -35.05% | -20.94% | -6.31% | +8.42% | -8.98% | +11.86% | -0.48% | -4.16% | -28.27% | +4851.12% | n/a |
| Neuroscience Revenue | 351.8M | 389.1M | 1.77B | 387.2M | 360.5M | 373.2M | 389.9M | 397.7M | 450.2M | 512.2M | 465.4M | 470.7M | 422.5M | 463.5M | 426.7M | 452.7M | 393.1M | 643.7M | 721.7M | 724.5M | 763.9M | 725.3M | 868.5M | 882.4M | 858.4M | 764.3M | 874.4M | 821.8M | 808.1M | 764.2M | 839.2M | 791.7M | 846.8M | 803.9M | 825.8M | 2.41B |
| Neuroscience Revenue Growth | -9.59% | -77.99% | +356.64% | +7.41% | -3.40% | -4.28% | -1.96% | -11.66% | -12.10% | +10.06% | -1.13% | +11.41% | -8.85% | +8.62% | -5.74% | +15.16% | -38.93% | -10.81% | -0.39% | -5.16% | +5.32% | -16.49% | -1.58% | +2.80% | +12.31% | -12.59% | +6.40% | +1.70% | +5.74% | -8.94% | +6.00% | -6.51% | +5.34% | -2.65% | -65.66% | n/a |
| Oncology Revenue | 2.23B | 1.81B | 1.75B | 1.67B | 1.36B | 1.29B | 1.37B | 1.35B | 1.41B | 1.55B | 1.37B | 1.33B | 1.27B | 1.2B | 1.15B | 1.2B | 1.01B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 59.5M | 839.9M |
| Oncology Revenue Growth | +23.30% | +3.60% | +4.55% | +23.23% | +4.85% | -5.51% | +1.16% | -3.78% | -9.52% | +13.25% | +2.91% | +5.11% | +5.58% | +4.72% | -4.16% | +18.22% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -92.92% | n/a |
| Other Product Revenue | 53.2M | 41.3M | 42.9M | 51M | 52.8M | 66.6M | 80.1M | 98.1M | 88.8M | 64.6M | 107.5M | 97M | 97.6M | 174.7M | 119.2M | 123.3M | 113.4M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Product Revenue Growth | +28.81% | -3.73% | -15.88% | -3.41% | -20.72% | -16.85% | -18.35% | +10.47% | +37.46% | -39.91% | +10.82% | -0.61% | -44.13% | +46.56% | -3.33% | +8.73% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Quarter | Dec 31, 2024 | Dec 30, 2023 | Dec 30, 2022 | Dec 30, 2021 | Dec 30, 2020 | Dec 30, 2019 | Dec 30, 2018 | Dec 30, 2017 | Dec 30, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Revenue | 1.66B | 6.17B | 4.3B | 4.78B | 4.19B | 3.77B | 4.23B | 3.94B | 3.77B | 3.94B | 4.51B | 4.34B | 4.26B |
| China Revenue Growth | -73.11% | +43.62% | -10.00% | +14.07% | +11.23% | -11.02% | +7.30% | +4.65% | -4.45% | -12.49% | +3.88% | +1.85% | n/a |
| Europe Revenue | 6.92B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 2.03B | 2.03B | n/a | n/a |
| Europe Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | +0.30% | n/a | n/a | n/a |
| Japan Revenue | 1.81B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 10.1B | 9.13B | n/a | n/a |
| Japan Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | +10.55% | n/a | n/a | n/a |
| United States Revenue | 30.38B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Quarter | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.42B | 2.1B | 2.12B | 1.95B | 1.92B | 1.8B | 1.93B | 1.75B | 1.64B | 1.61B | 1.63B | 1.56B | 1.59B | 1.58B | 1.69B | 1.58B | 1.55B | 1.57B | 1.45B | 1.55B | 1.7B | 1.41B | 1.59B | 1.52B | 1.86B | 1.62B | 1.65B | 1.5B | 1.78B | 1.56B | 1.71B | 1.54B | 1.79B | 1.57B | 1.62B | 1.47B | 1.8B | 1.58B | 1.64B | 1.52B |
| Selling, General, and Administrative Revenue Growth | +15.46% | -0.83% | +8.46% | +1.43% | +6.69% | -6.31% | +10.07% | +6.45% | +1.80% | -0.67% | +4.31% | -2.14% | +0.89% | -6.39% | +6.96% | +1.42% | -0.97% | +8.32% | -6.52% | -8.75% | +20.24% | -10.97% | +4.56% | -18.50% | +15.15% | -2.24% | +10.25% | -15.75% | +14.46% | -8.90% | +10.53% | -13.71% | +14.35% | -3.53% | +10.09% | -18.04% | +14.13% | -3.65% | +7.34% | n/a |
| Research and Development Revenue | 3.21B | 2.73B | 2.71B | 2.52B | 2.56B | 2.41B | 2.36B | 1.99B | 2B | 1.8B | 1.78B | 1.61B | 1.96B | 1.71B | 1.67B | 1.68B | 1.84B | 1.47B | 1.39B | 1.39B | 1.58B | 1.38B | 1.4B | 1.23B | 1.45B | 1.34B | 1.33B | 1.18B | 1.47B | 1.32B | 1.25B | 1.24B | 1.45B | 1.24B | 1.34B | 1.22B | 1.44B | 1.14B | 1.17B | 1.04B |
| Research and Development Revenue Growth | +17.47% | +0.84% | +7.47% | -1.56% | +6.38% | +2.23% | +18.71% | -0.54% | +10.70% | +1.18% | +10.67% | -17.83% | +14.66% | +2.16% | -0.71% | -8.34% | +25.43% | +5.41% | -0.14% | -11.97% | +14.52% | -1.52% | +13.95% | -15.36% | +8.23% | +0.77% | +13.27% | -20.11% | +11.66% | +5.48% | +1.02% | -14.64% | +17.32% | -7.45% | +9.41% | -15.45% | +26.31% | -2.23% | +12.53% | n/a |
| Sales and Marketing Revenue | 461.7M | n/a | 114.4M | 116.1M | 461.9M | n/a | n/a | n/a | 1B | 92.4M | 94.3M | n/a | 1.2B | n/a | 71.1M | n/a | 1.1B | n/a | 1.45B | 1.55B | 1.7B | 1.41B | 1.59B | 1.52B | 1.86B | 1.62B | 1.65B | 1.5B | 1.78B | 1.56B | 1.71B | 1.54B | 1.79B | 1.57B | 1.62B | 1.47B | 1.8B | 1.58B | 1.64B | 1.52B |
| Sales and Marketing Revenue Growth | n/a | -100.00% | -1.46% | -74.86% | n/a | n/a | n/a | -100.00% | +982.25% | -2.01% | n/a | -100.00% | n/a | -100.00% | n/a | -100.00% | n/a | -100.00% | -6.52% | -8.75% | +20.24% | -10.97% | +4.56% | -18.50% | +15.15% | -2.24% | +10.25% | -15.75% | +14.46% | -8.90% | +10.53% | -13.71% | +14.35% | -3.53% | +10.09% | -18.04% | +14.13% | -3.65% | +7.34% | n/a |